Most of the GLP-1 drugs studied in this group, of which there are several, remain largely under patent protection
NICE guidelines (NG28) support the use of GLP-1 receptor agonists for type 2 diabetes when glycaemic targets are not achieved with other therapies, and for weight management in specific circumstances (TA875 for Wegovy, TA664 for Saxenda)
The placebo group had a baseline weight of 73.1 1 kg and an end weight of 73.9 0.9 kg, while the NAC group had a baseline weight of 72.12 9.7 kg and an end weight of 72.12 4.6 kg
As with other GLP-1 medicines, they are generally not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN2, and caution is needed in people with certain gastrointestinal issues, pancreatitis concerns, gallbladder disease, or other relevant medical conditions
A 10-day wait reduces tirzepatide to approximately 25% of peak levels
For instance, while liraglutide may utilize a simple up-titration schedule over several weeks, exenatide could require more frequent dose adjustments dependent on glucose regulation and weight fluctuations
